AERIE PHARMACEUTICALS INC (AERI)
US00771V1089 - Common Stock
Overall AERI gets a fundamental rating of 2 out of 10. We evaluated AERI against 198 industry peers in the Pharmaceuticals industry. AERI has a bad profitability rating. Also its financial health evaluation is rather negative. AERI shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year AERI has reported negative net income.
AERI had a positive operating cash flow in the past year.
AERI had negative earnings in each of the past 5 years.
AERI had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.73% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | -12.49% | ||
| PM (TTM) | -17.09% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
AERI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, AERI has more shares outstanding
The debt/assets ratio for AERI is higher compared to a year ago.
2.2 Solvency
AERI has an Altman-Z score of -2.71. This is a bad value and indicates that AERI is not financially healthy and even has some risk of bankruptcy.
AERI has a debt to FCF ratio of 118.54. This is a negative value and a sign of low solvency as AERI would need 118.54 years to pay back of all of its debts.
AERI has a Debt/Equity ratio of -1.91. This is a healthy value indicating a solid balance between debt and equity.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | -1.91 | ||
| Debt/FCF | 118.54 | ||
| Altman-Z | -2.71 |
ROIC/WACCN/A
WACC8.3%
2.3 Liquidity
AERI has a Current Ratio of 2.27. This indicates that AERI is financially healthy and has no problem in meeting its short term obligations.
AERI has a Quick Ratio of 1.92. This is a normal value and indicates that AERI is financially healthy and should not expect problems in meeting its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.92 |
3. Growth
3.1 Past
AERI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 94.48%, which is quite impressive.
Looking at the last year, AERI shows a very strong growth in Revenue. The Revenue has grown by 105.42%.
The Revenue has been growing by 100.24% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)94.48%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q62.5%
Revenue 1Y (TTM)105.42%
Revenue growth 3Y100.24%
Revenue growth 5YN/A
Revenue growth Q2Q23.25%
3.2 Future
The Earnings Per Share is expected to grow by 12.85% on average over the next years. This is quite good.
The Revenue is expected to grow by 21.90% on average over the next years. This is a very strong growth
EPS Next Y-85.62%
EPS Next 2Y-0.49%
EPS Next 3Y24.72%
EPS Next 5Y12.85%
Revenue Next Year23.8%
Revenue Next 2Y27.33%
Revenue Next 3Y26.9%
Revenue Next 5Y21.9%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
AERI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AERI. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 285.78 | ||
| EV/EBITDA | -38.22 |
4.3 Compensation for Growth
A more expensive valuation may be justified as AERI's earnings are expected to grow with 24.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.49%
EPS Next 3Y24.72%
5. Dividend
5.1 Amount
No dividends for AERI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AERIE PHARMACEUTICALS INC
NASDAQ:AERI (11/18/2022, 7:21:01 PM)
After market: 15.25 0 (0%)15.25
+0.01 (+0.07%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap753.62M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -9.73% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | -12.49% | ||
| PM (TTM) | -17.09% | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | -1.91 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.27 | ||
| Quick Ratio | 1.92 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)94.48%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-85.62%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)105.42%
Revenue growth 3Y100.24%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y